Treatment with five-fraction SBRT for prostate cancer may be more convenient than receiving traditional radiation therapy techniques, an expert said. For patients with low- to intermediate-risk ...
In patients with localized prostate cancer, stereotactic body radiotherapy (SBRT) was associated with better urinary continence and sexual function, but slightly worse bowel function, compared with ...
The phase 3 NRG GU-005 trial did not show a DFS benefit for SBRT vs IMRT in intermediate-risk prostate cancer, but SBRT decreased rectal toxicity. Stereotactic body radiation therapy (SBRT) preserves ...
Using MRI instead of CT guidance to zero in on prostate tumors enables more precise delivery of SBRT and lowers side effect rates. MRI vs CT guidance reduces side effects from prostate cancer ...
WASHINGTON — MRI-guided stereotactic body radiotherapy (SBRT) showed sustained benefits over CT-guided SBRT for prostate cancer, in a study. Amar Kishan, MD, of UCLA Health, presented the 2-year ...
Please provide your email address to receive an email when new articles are posted on . Five-fraction SBRT appeared noninferior to conventional radiotherapy. Grade 2 or higher gastrointestinal adverse ...
Stereotactic body radiotherapy (SBRT) showed good local control and survival for limited metastatic/progressive cancers. Two-thirds of patients were alive at 2 years with minimal serious toxicity ...
For patients with intermediate-risk, localized prostate cancer, radiation therapy delivered in five sessions reduced patient-reported side effects compared to longer courses of radiation, according to ...
Physicians and scientists from the UCLA Health Jonsson Comprehensive Cancer Center will share the latest research and clinical trial results at the 2025 American Society for Radiation Oncology (ASTRO) ...
MiraDx, a molecular diagnostics company focused on genetic testing to personalize cancer treatment, today announced the U.S.
Addition of 6 months of androgen deprivation therapy to stereotactic body radiotherapy more than doubled PFS in hormone-sensitive oligorecurrent prostate cancer. Nearly all patients treated with the ...
The assay is designed to encourage informed patient-physician decision-making when choosing a treatment option in localised ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results